The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with ...

Helen Bender, from Alabama, United States, was devastated to learn she had 20 tumours, all originating from a seemingly ...

Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns ...

Aura Biosciences (AURA) has reported its Q4 and full-year 2024 financial results, prompting an ongoing decline in shares ...

We recently published a list of Top 10 Penny Stocks That Will Skyrocket. In this article, we are going to take a look at ...

New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell ...

As of December 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $151.1 million. The Company believes its current cash and cash equivalents and marketable securities are ...

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

To fight this, doctors often use drugs called BRAF inhibitors, such as vemurafenib, which can stop the cancer’s growth—at ...

A research team led by Sheri Holmen, Ph.D., investigator at Huntsman Cancer Institute and professor in the Department of Surgery at the University of Utah (the U), is testing a new combination drug ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...